{"id":407279,"date":"2021-01-04T07:03:35","date_gmt":"2021-01-04T12:03:35","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=407279"},"modified":"2021-01-04T07:03:35","modified_gmt":"2021-01-04T12:03:35","slug":"leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Leap Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">CAMBRIDGE, Mass.<\/span>, <span class=\"xn-chron\">Jan. 4, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that <span class=\"xn-person\">Douglas E. Onsi<\/span>, President and Chief Executive Officer, will present a corporate overview at the 39<sup>th<\/sup> Annual J.P. Morgan Healthcare Conference. The conference will be held in a virtual meeting format. <\/p>\n<p>\n        <b>Leap Presentation Details:<\/b>\n      <\/p>\n<p>39<sup>th<\/sup> Annual J.P. Morgan Healthcare Conference <br \/>Date: <span class=\"xn-chron\">Thursday, January 14<\/span><br \/>Time: <span class=\"xn-chron\">3:40 p.m. Eastern Time<\/span><\/p>\n<p>The presentation will be webcast live and may be accessed on the Investors page of the company&#8217;s website at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3023333-1&amp;h=1517489213&amp;u=https%3A%2F%2Finvestors.leaptx.com%2F&amp;a=https%3A%2F%2Finvestors.leaptx.com%2F\" rel=\"nofollow noopener noreferrer\">https:\/\/investors.leaptx.com\/<\/a>, where a replay of the event will also be available for a limited time.<\/p>\n<p>\n        <b>About Leap Therapeutics<\/b>\n      <\/p>\n<p>Leap Therapeutics\u00a0(Nasdaq:LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap&#8217;s most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 <span class=\"xn-money\">(DKK1)<\/span> protein. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in <span class=\"xn-location\">Asia<\/span> (excluding <span class=\"xn-location\">Japan<\/span>), <span class=\"xn-location\">Australia<\/span>, and <span class=\"xn-location\">New Zealand<\/span>. For more information about Leap Therapeutics, visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3023333-1&amp;h=2530677249&amp;u=http%3A%2F%2Fwww.leaptx.com%2F&amp;a=http%3A%2F%2Fwww.leaptx.com\" rel=\"nofollow noopener noreferrer\">http:\/\/www.leaptx.com<\/a> or view our public filings with the SEC that are available via EDGAR at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3023333-1&amp;h=3179166091&amp;u=http%3A%2F%2Fwww.sec.gov%2F&amp;a=http%3A%2F%2Fwww.sec.gov\" rel=\"nofollow noopener noreferrer\">http:\/\/www.sec.gov<\/a> or via <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3023333-1&amp;h=1517489213&amp;u=https%3A%2F%2Finvestors.leaptx.com%2F&amp;a=https%3A%2F%2Finvestors.leaptx.com%2F\" rel=\"nofollow noopener noreferrer\">https:\/\/investors.leaptx.com\/<\/a>.<\/p>\n<p>\n        <b>FORWARD-LOOKING STATEMENTS<\/b>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include Leap&#8217;s expectations with respect to the development and advancement of DKN-01, including the initiation, timing and design of future studies, enrollment in future studies, potential for the receipt of future option exercise, milestones or royalty payments from BeiGene, and other future expectations, plans and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to: that the initiation, conduct, and completion of clinical trials, laboratory operations, manufacturing campaigns, and other studies may be delayed, adversely affected, or impacted by COVID-19 related issues; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially will be included in Leap Therapeutics&#8217; periodic filings with the SEC, including Leap&#8217;s Annual Report on Form 10-K for the fiscal year ended <span class=\"xn-chron\">December 31, 2019<\/span>, as filed with the SEC on <span class=\"xn-chron\">March 16, 2020<\/span> and as may be updated by Leap&#8217;s Quarterly Reports on Form 10-Q and the other reports Leap files from time to time with the SEC. Any forward-looking statements contained in this release speak only as of its date. Leap undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.<\/p>\n<p>\n        <b>CONTACT:<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Douglas E. Onsi<\/span><br \/>\n        <br \/>President &amp; Chief Executive Officer<br \/>Leap Therapeutics, Inc.<br \/>617-714-0360<br \/><a target=\"_blank\" href=\"mailto:donsi@leaptx.com\" rel=\"nofollow noopener noreferrer\">donsi@leaptx.com<\/a><\/p>\n<p>\n        <span class=\"xn-person\">Heather Savelle<\/span><br \/>\n        <br \/>Investor Relations <br \/>Argot Partners<br \/>212-600-1902<br \/><a target=\"_blank\" href=\"mailto:heather@argotpartners.com\" rel=\"nofollow noopener noreferrer\">heather@argotpartners.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder3118\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/737463\/Leap_Therapeutics_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/737463\/Leap_Therapeutics_Logo.jpg\" title=\"Leap Therapeutics logo (PRNewsfoto\/LEAP Therapeutics)\" alt=\"Leap Therapeutics logo (PRNewsfoto\/LEAP Therapeutics)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE34575&amp;sd=2021-01-04\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/leap-therapeutics-to-present-at-39th-annual-jp-morgan-healthcare-conference-301199091.html\">http:\/\/www.prnewswire.com\/news-releases\/leap-therapeutics-to-present-at-39th-annual-jp-morgan-healthcare-conference-301199091.html<\/a><\/p>\n<p>SOURCE  Leap Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE34575&amp;Transmission_Id=202101040700PR_NEWS_USPR_____NE34575&amp;DateId=20210104\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire CAMBRIDGE, Mass., Jan. 4, 2021 \/PRNewswire\/ &#8212;\u00a0Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference. The conference will be held in a virtual meeting format. Leap Presentation Details: 39th Annual J.P. Morgan Healthcare Conference Date: Thursday, January 14Time: 3:40 p.m. Eastern Time The presentation will be webcast live and may be accessed on the Investors page of the company&#8217;s website at https:\/\/investors.leaptx.com\/, where a replay of the event will also be available for a limited time. About Leap Therapeutics Leap Therapeutics\u00a0(Nasdaq:LPTX) is focused on developing targeted and immuno-oncology therapeutics. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Leap Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-407279","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Leap Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leap Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire CAMBRIDGE, Mass., Jan. 4, 2021 \/PRNewswire\/ &#8212;\u00a0Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference. The conference will be held in a virtual meeting format. Leap Presentation Details: 39th Annual J.P. Morgan Healthcare Conference Date: Thursday, January 14Time: 3:40 p.m. Eastern Time The presentation will be webcast live and may be accessed on the Investors page of the company&#8217;s website at https:\/\/investors.leaptx.com\/, where a replay of the event will also be available for a limited time. About Leap Therapeutics Leap Therapeutics\u00a0(Nasdaq:LPTX) is focused on developing targeted and immuno-oncology therapeutics. &hellip; Continue reading &quot;Leap Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-04T12:03:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/737463\/Leap_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Leap Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2021-01-04T12:03:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":648,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/737463\\\/Leap_Therapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Leap Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/737463\\\/Leap_Therapeutics_Logo.jpg\",\"datePublished\":\"2021-01-04T12:03:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/737463\\\/Leap_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/737463\\\/Leap_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leap Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Leap Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Leap Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"PR Newswire CAMBRIDGE, Mass., Jan. 4, 2021 \/PRNewswire\/ &#8212;\u00a0Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference. The conference will be held in a virtual meeting format. Leap Presentation Details: 39th Annual J.P. Morgan Healthcare Conference Date: Thursday, January 14Time: 3:40 p.m. Eastern Time The presentation will be webcast live and may be accessed on the Investors page of the company&#8217;s website at https:\/\/investors.leaptx.com\/, where a replay of the event will also be available for a limited time. About Leap Therapeutics Leap Therapeutics\u00a0(Nasdaq:LPTX) is focused on developing targeted and immuno-oncology therapeutics. &hellip; Continue reading \"Leap Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-04T12:03:35+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/737463\/Leap_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Leap Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference","datePublished":"2021-01-04T12:03:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/"},"wordCount":648,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/737463\/Leap_Therapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/","name":"Leap Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/737463\/Leap_Therapeutics_Logo.jpg","datePublished":"2021-01-04T12:03:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/737463\/Leap_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/737463\/Leap_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Leap Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/407279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=407279"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/407279\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=407279"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=407279"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=407279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}